European healthcare policies for controlling drug expenditure.
about
Pharmaceutical policies: effects of cap and co-payment on rational use of medicinesPharmaceutical policies: effects of financial incentives for prescribersPharmaceutical policies: effects of cap and co-payment on rational drug usePharmaceutical policies: effects of financial incentives for prescribersThe experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine useMedicines prices and Malaysia--untangling the medicines webPhysician awareness of drug cost: a systematic reviewA systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and developmentThe case for open-access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discoveryClearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicinePharmacists' views and reported practices in relation to a new generic drug substitution policy in Lebanon: a mixed methods study.Pharmaceutical cost control in primary care: opinion and contributions by healthcare professionals.Influence of mandatory generic substitution on pharmaceutical sales patterns: a national study over five years.Does the pharmacy expenditure of patients always correspond with their morbidity burden? Exploring new approaches in the interpretation of pharmacy expenditure.Generic drug prescribing in central Saudi Arabia: perceptions and attitudes of physicians.Statistical and regulatory considerations in assessments of interchangeability of biological drug products.Analyzing generic and branded substitution patterns in the Netherlands using prescription dataReference drug programs: effectiveness and policy implications.Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain.Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan.The impact of regional co-payment and national reimbursement criteria on statins use in Italy: an interrupted time-series analysis.Policies to enhance prescribing efficiency in europe: findings and future implications.Physicians' perception of generic and electronic prescribing: A descriptive study from JordanPrescribing Generic Medication in Chronic Musculoskeletal Pain Patients: An Issue of Representations, Trust, and Experience in a Swiss CohortIs cost-related non-collection of prescriptions associated with a reduction in health? Findings from a large-scale longitudinal study of New Zealand adultsThe influence of health insurance scheme on the drug prescribing pattern in a Nigerian tertiary healthcare facilityDifferent angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction.The New and Old Europe: East-West Split in Pharmaceutical Spending.Factors influencing the variation in GMS prescribing expenditure in IrelandUse of statins and beta-blockers after acute myocardial infarction according to income and education.The impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic medication in Finland.Factors Contributing to Increases in Prescription Drug Expenditures Borne by National Health Insurance in South Korea.Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations.Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries.Register-based indicators for potentially inappropriate medication in high-cost patients with excessive polypharmacy.Proton pump inhibitors prescribing following the introduction of generic drugs.Introduction of therapeutic reference pricing in Slovenia and its economic consequences.What drives the prescribing of growth hormone preparations in England? Prices versus patient preferences.U.S. pharmacy policy: a public health perspective on safety and cost.The impact of physician-level drug budgets on prescribing behavior.
P2860
Q24188009-32CFCABF-3147-4B43-BAD3-416008F5694AQ24188018-3A5909BC-577A-4242-86B3-B7EFF483E26CQ24242490-C1BB34A7-CD28-4F81-A977-D678E8E014B5Q24243902-AC27D7A9-5650-41A7-B724-EB212F35F138Q27007695-22FB6C1D-7F66-4523-BB57-817A703DC50FQ28469171-3EB4C9D0-DBF8-4223-AF2E-D48DAB63C5C4Q28469310-744AA9CB-0EE3-4D8D-8147-548D5C11494CQ28540727-43EC4AA7-439C-48E0-A43F-3E3EA55BDEFAQ28751328-BB06E21B-8CF1-40CC-B441-9DE0828D6538Q28756810-6CE7128E-737D-44E7-9DB1-F5AA502713DCQ30839146-F03DF91A-5FB6-46A8-9090-D749A836EEF3Q30891473-CA8FABA6-9777-48CF-8E5C-4EA72CD1C42FQ33321951-0E74ED8E-B62F-4CEC-BC04-5303A0EC1199Q33575638-3696D66F-FB3D-4BB6-9226-6CAC7FF8C137Q33619480-D7EF57B7-1C78-4360-B324-F4A665DD0BF9Q33713246-25E6567E-5FEF-432D-825A-23D4204DB140Q33882893-60061697-CE18-41AA-AFDA-D3D986BEBA00Q33908085-5DE1154D-630E-458A-B7BC-2EA8D44F6CD2Q34218399-33BDC3DB-DAA2-4F2B-B512-CEDDCBE1CC6FQ34240897-2834598F-6643-4B81-8BB7-8B50DE8FC20BQ35083824-19A0E4A2-F67A-4A36-9CDF-28DFD39AE578Q35155250-DCDE55AC-97D6-490F-B3CE-D567A6EB5678Q35198487-9148ACBF-0905-4627-B5DE-7161D21C58FFQ35734796-4B9BE33F-77CF-47B7-A01A-191CADDCC47DQ36302740-D3B90233-6A82-4F1C-9FF7-69E768D69546Q36423717-A4D1C7AE-FB6C-4594-A9AA-6ADB119DA813Q36535869-878B9AEA-30FE-4F39-B7C8-E93EA4041690Q36633030-1F055725-019C-4E21-9061-323A47C17996Q36740022-446554BB-9B3A-4CEE-AA61-F80C77A15E2EQ36768920-E297F4EF-5661-4BDB-880E-B267A0093854Q36944475-C0E1B1B0-9F3C-401E-9EBC-41ECA6562CB6Q37110112-13D07E94-0818-4BD5-9B7D-838EF90D1967Q37261320-98D5ED8B-E6A4-4734-B9CD-846FC2DA766DQ38178581-26678008-BA03-4996-B2EC-2E0915959C05Q38366452-DFB3BD90-397F-47A7-AFC1-AB57F6D5C55BQ38432208-EC9595C2-1367-403B-BF34-E1C8AA21A18BQ38759833-3F81A24A-9E79-4FA7-AB2A-A46F57DDD746Q38841536-F1E23421-FC38-4586-B4EC-6D1CC46D6B8DQ39939660-0CF8DCBA-C111-45BB-9370-63051E114C60Q40337317-62EFC834-0CCF-49F3-A979-EC81D67B74A7
P2860
European healthcare policies for controlling drug expenditure.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
European healthcare policies for controlling drug expenditure.
@ast
European healthcare policies for controlling drug expenditure.
@en
type
label
European healthcare policies for controlling drug expenditure.
@ast
European healthcare policies for controlling drug expenditure.
@en
prefLabel
European healthcare policies for controlling drug expenditure.
@ast
European healthcare policies for controlling drug expenditure.
@en
P2093
P1433
P1476
European healthcare policies for controlling drug expenditure.
@en
P2093
Sebastian Schneeweiss
Silvia M Ess
Thomas D Szucs
P304
P356
10.2165/00019053-200321020-00002
P577
2003-01-01T00:00:00Z
P6179
1016091229